ATHA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATHA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Athira Pharma's Enterprise Value is $-61.90 Mil. Athira Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-126.94 Mil. Therefore, Athira Pharma's EV-to-EBIT ratio for today is 0.49.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Athira Pharma's Enterprise Value is $-61.90 Mil. Athira Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-125.97 Mil. Therefore, Athira Pharma's EV-to-EBITDA ratio for today is 0.49.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Athira Pharma's Enterprise Value is $-61.90 Mil. Athira Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Athira Pharma's EV-to-Revenue ratio for today is .
The historical data trend for Athira Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athira Pharma Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Enterprise Value | Get a 7-Day Free Trial | - | 928.96 | 235.21 | -78.36 | -53.07 |
Athira Pharma Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Enterprise Value | Get a 7-Day Free Trial | -78.36 | -89.27 | -72.07 | -94.41 | -53.07 |
For the Biotechnology subindustry, Athira Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Athira Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Athira Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Athira Pharma's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 92.759418 | + | 0 | + | 1.217 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.368 | + | 0 | - | 147.419 |
= | -53.07 |
Athira Pharma's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value (Q: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 92.759418 | + | 0 | + | 1.217 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.368 | + | 0 | - | 147.419 |
= | -53.07 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athira Pharma (NAS:ATHA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Athira Pharma's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -61.899 | / | -126.937 | |
= | 0.49 |
Athira Pharma's current Enterprise Value is $-61.90 Mil.
Athira Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-126.94 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Athira Pharma's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | -61.899 | / | -125.968 | |
= | 0.49 |
Athira Pharma's current Enterprise Value is $-61.90 Mil.
Athira Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-125.97 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Athira Pharma's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | -61.899 | / | 0 | |
= |
Athira Pharma's current Enterprise Value is $-61.90 Mil.
Athira Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Athira Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark James Litton | officer: Chief Operating Officer | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Mark Worthington | officer: General Counsel | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011 |
Rachel Lenington | officer: Chief Technology Officer | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Andrew Gengos | officer: See Below | 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367 |
Grant Pickering | director | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
James A Johnson | director | C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102 |
Kevin Church | officer: Vice President of Discovery | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Glenna Mileson | officer: Chief Financial Officer | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Kelly A Romano | director | C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915 |
Hans Moebius | officer: Chief Medical Officer | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Michael A. Panzara | director | 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
Barbara Kosacz | director | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
From GuruFocus
By sperokesalga sperokesalga • 04-25-2023
By Marketwired • 10-05-2023
By sperokesalga sperokesalga • 05-31-2023
By sperokesalga sperokesalga • 03-23-2023
By sperokesalga sperokesalga • 05-08-2023
By Value_Insider Value_Insider • 11-07-2022
By Marketwired • 09-28-2023
By Value_Insider Value_Insider • 11-29-2022
By Stock market mentor Stock market mentor • 02-01-2023
By Value_Insider Value_Insider • 11-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.